# PeptideScanner evidence objects: Etelcalcetide

Every published version of the records placed with Etelcalcetide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json. Selected public evidence only; not medical advice.

- Objects: 47
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct01134549-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01134549

> PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01134549-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01134549-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01134549-etelcalcetide-v1
- Content SHA-256: `9baa489fa485ddb4d06e3f2c2de1cb025ab528c3eaaa2899d60bbb2dbaee96ff`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01134549 ([`ctg-observation-nct01134549-2017-04-14-e162a3eb799f`](#source-ctg-observation-nct01134549-2017-04-14-e162a3eb799f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01134549-2017-04-14-e162a3eb799f`](#source-ctg-observation-nct01134549-2017-04-14-e162a3eb799f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01134549-2017-04-14-e162a3eb799f`](#source-ctg-observation-nct01134549-2017-04-14-e162a3eb799f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01134549-2017-04-14-e162a3eb799f`](#source-ctg-observation-nct01134549-2017-04-14-e162a3eb799f))

### Sources

<a id="source-ctg-observation-nct01134549-2017-04-14-e162a3eb799f"></a>
- **ClinicalTrials.gov record NCT01134549 · retained source version 2017-04-14:e162a3eb799f443f5a0de07c0c5de323fb5ddbb7b7718166e7adcebbad9f76ec** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01134549) (`ctg-observation-nct01134549-2017-04-14-e162a3eb799f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01134549." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01134549-etelcalcetide-v1 SHA-256: 9baa489fa485ddb4d06e3f2c2de1cb025ab528c3eaaa2899d60bbb2dbaee96ff.

---

<a id="clinicaltrials-gov-nct01134562-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01134562

> PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01134562-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01134562-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01134562-etelcalcetide-v1
- Content SHA-256: `315e212fb82e4d86275122785e5a456efa959c8319a0e0acf04b9f2335fa42b5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01134562 ([`ctg-observation-nct01134562-2018-01-02-94c38b2079c6`](#source-ctg-observation-nct01134562-2018-01-02-94c38b2079c6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01134562-2018-01-02-94c38b2079c6`](#source-ctg-observation-nct01134562-2018-01-02-94c38b2079c6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01134562-2018-01-02-94c38b2079c6`](#source-ctg-observation-nct01134562-2018-01-02-94c38b2079c6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01134562-2018-01-02-94c38b2079c6`](#source-ctg-observation-nct01134562-2018-01-02-94c38b2079c6))

### Sources

<a id="source-ctg-observation-nct01134562-2018-01-02-94c38b2079c6"></a>
- **ClinicalTrials.gov record NCT01134562 · retained source version 2018-01-02:94c38b2079c6ac16baef8e464c54252922b7e163b1e93660ad20e3ce36dbc704** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01134562) (`ctg-observation-nct01134562-2018-01-02-94c38b2079c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01134562." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01134562-etelcalcetide-v1 SHA-256: 315e212fb82e4d86275122785e5a456efa959c8319a0e0acf04b9f2335fa42b5.

---

<a id="clinicaltrials-gov-nct01254565-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01254565

> PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01254565-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01254565-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01254565-etelcalcetide-v1
- Content SHA-256: `0a393b412e08c1fc20de9b1dc6866acea1735f2ecf418c3d9270a5021a586fb1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01254565 ([`ctg-observation-nct01254565-2017-04-13-d5af4bd52a16`](#source-ctg-observation-nct01254565-2017-04-13-d5af4bd52a16))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01254565-2017-04-13-d5af4bd52a16`](#source-ctg-observation-nct01254565-2017-04-13-d5af4bd52a16))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01254565-2017-04-13-d5af4bd52a16`](#source-ctg-observation-nct01254565-2017-04-13-d5af4bd52a16))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01254565-2017-04-13-d5af4bd52a16`](#source-ctg-observation-nct01254565-2017-04-13-d5af4bd52a16))

### Sources

<a id="source-ctg-observation-nct01254565-2017-04-13-d5af4bd52a16"></a>
- **ClinicalTrials.gov record NCT01254565 · retained source version 2017-04-13:d5af4bd52a168b7f4476ccaeec3df9f9759e97b9a12eee7d434cb9bfa9875050** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01254565) (`ctg-observation-nct01254565-2017-04-13-d5af4bd52a16`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01254565." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01254565-etelcalcetide-v1 SHA-256: 0a393b412e08c1fc20de9b1dc6866acea1735f2ecf418c3d9270a5021a586fb1.

---

<a id="clinicaltrials-gov-nct01414114-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01414114

> PeptideScanner retained ClinicalTrials.gov record NCT01414114 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01414114-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01414114-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01414114-etelcalcetide-v1
- Content SHA-256: `4eb1c8e9cfbc0bccbe18a02476c52429a876d3bcf04369c18b2fd8157c7c4340`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01414114 ([`ctg-observation-nct01414114-2017-04-11-905af0b0b055`](#source-ctg-observation-nct01414114-2017-04-11-905af0b0b055))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01414114 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01414114-2017-04-11-905af0b0b055`](#source-ctg-observation-nct01414114-2017-04-11-905af0b0b055))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01414114 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01414114-2017-04-11-905af0b0b055`](#source-ctg-observation-nct01414114-2017-04-11-905af0b0b055))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01414114-2017-04-11-905af0b0b055`](#source-ctg-observation-nct01414114-2017-04-11-905af0b0b055))

### Sources

<a id="source-ctg-observation-nct01414114-2017-04-11-905af0b0b055"></a>
- **ClinicalTrials.gov record NCT01414114 · retained source version 2017-04-11:905af0b0b055d68ac2166a6f04b0e5e3fffff9585777103f3d8d9dd8d54f3fd9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01414114) (`ctg-observation-nct01414114-2017-04-11-905af0b0b055`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01414114." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01414114-etelcalcetide-v1 SHA-256: 4eb1c8e9cfbc0bccbe18a02476c52429a876d3bcf04369c18b2fd8157c7c4340.

---

<a id="clinicaltrials-gov-nct01785849-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01785849

> PeptideScanner retained ClinicalTrials.gov record NCT01785849 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01785849-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-08-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01785849-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01785849-etelcalcetide-v1
- Content SHA-256: `21c52cb0c4bb555dd72122961ce8dd243806dc0fd397f5cef93711b6554da498`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01785849 ([`ctg-observation-nct01785849-2019-08-26-e147421c3cb9`](#source-ctg-observation-nct01785849-2019-08-26-e147421c3cb9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01785849 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01785849-2019-08-26-e147421c3cb9`](#source-ctg-observation-nct01785849-2019-08-26-e147421c3cb9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01785849 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01785849-2019-08-26-e147421c3cb9`](#source-ctg-observation-nct01785849-2019-08-26-e147421c3cb9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01785849-2019-08-26-e147421c3cb9`](#source-ctg-observation-nct01785849-2019-08-26-e147421c3cb9))

### Sources

<a id="source-ctg-observation-nct01785849-2019-08-26-e147421c3cb9"></a>
- **ClinicalTrials.gov record NCT01785849 · retained source version 2019-08-26:e147421c3cb9bfc78e8be2c7d406059fba8cdac33569032d9783804cefd85d61** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01785849) (`ctg-observation-nct01785849-2019-08-26-e147421c3cb9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01785849." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01785849-etelcalcetide-v1 SHA-256: 21c52cb0c4bb555dd72122961ce8dd243806dc0fd397f5cef93711b6554da498.

---

<a id="clinicaltrials-gov-nct01785875-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01785875

> PeptideScanner retained ClinicalTrials.gov record NCT01785875 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-04-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01785875-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-04-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01785875-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01785875-etelcalcetide-v1
- Content SHA-256: `b5690976748d541e67c680c42abd0ac204ab6cd8376c8313d076ca5d9b21bef3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01785875 ([`ctg-observation-nct01785875-2019-04-10-362d2aceb3cf`](#source-ctg-observation-nct01785875-2019-04-10-362d2aceb3cf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01785875 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-04-10, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01785875-2019-04-10-362d2aceb3cf`](#source-ctg-observation-nct01785875-2019-04-10-362d2aceb3cf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01785875 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-04-10, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01785875-2019-04-10-362d2aceb3cf`](#source-ctg-observation-nct01785875-2019-04-10-362d2aceb3cf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01785875-2019-04-10-362d2aceb3cf`](#source-ctg-observation-nct01785875-2019-04-10-362d2aceb3cf))

### Sources

<a id="source-ctg-observation-nct01785875-2019-04-10-362d2aceb3cf"></a>
- **ClinicalTrials.gov record NCT01785875 · retained source version 2019-04-10:362d2aceb3cfdd2babed6a978152434d713b4af85ba0b6e9f0dc393685f60a42** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01785875) (`ctg-observation-nct01785875-2019-04-10-362d2aceb3cf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01785875." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01785875-etelcalcetide-v1 SHA-256: b5690976748d541e67c680c42abd0ac204ab6cd8376c8313d076ca5d9b21bef3.

---

<a id="clinicaltrials-gov-nct01788046-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01788046

> PeptideScanner retained ClinicalTrials.gov record NCT01788046 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-20, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01788046-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-08-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01788046-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01788046-etelcalcetide-v1
- Content SHA-256: `89fad0488866182726c82509e6a9d6c8a656101443942a38419cb9a02a504e5c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01788046 ([`ctg-observation-nct01788046-2019-08-20-be650b39b322`](#source-ctg-observation-nct01788046-2019-08-20-be650b39b322))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01788046 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-20, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01788046-2019-08-20-be650b39b322`](#source-ctg-observation-nct01788046-2019-08-20-be650b39b322))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01788046 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-08-20, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01788046-2019-08-20-be650b39b322`](#source-ctg-observation-nct01788046-2019-08-20-be650b39b322))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01788046-2019-08-20-be650b39b322`](#source-ctg-observation-nct01788046-2019-08-20-be650b39b322))

### Sources

<a id="source-ctg-observation-nct01788046-2019-08-20-be650b39b322"></a>
- **ClinicalTrials.gov record NCT01788046 · retained source version 2019-08-20:be650b39b322f65fc9ff82bfb418e66ff025a5bbf86cf4424afb89745ad57056** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01788046) (`ctg-observation-nct01788046-2019-08-20-be650b39b322`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01788046." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01788046-etelcalcetide-v1 SHA-256: 89fad0488866182726c82509e6a9d6c8a656101443942a38419cb9a02a504e5c.

---

<a id="clinicaltrials-gov-nct01896232-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01896232

> PeptideScanner retained ClinicalTrials.gov record NCT01896232 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-18, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01896232-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01896232-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01896232-etelcalcetide-v1
- Content SHA-256: `7e721c5f5c103029214a62b90e610c3070927a44658a996ab92892b5eb413651`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01896232 ([`ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5`](#source-ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01896232 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-18, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5`](#source-ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01896232 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-18, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5`](#source-ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5`](#source-ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5))

### Sources

<a id="source-ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5"></a>
- **ClinicalTrials.gov record NCT01896232 · retained source version 2019-07-18:eb33ff2ba7a5b8f304a37fdb41da209531183ecb280a8174ce184793fb6ef13c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01896232) (`ctg-observation-nct01896232-2019-07-18-eb33ff2ba7a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01896232." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01896232-etelcalcetide-v1 SHA-256: 7e721c5f5c103029214a62b90e610c3070927a44658a996ab92892b5eb413651.

---

<a id="clinicaltrials-gov-nct01932970-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT01932970

> PeptideScanner retained ClinicalTrials.gov record NCT01932970 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct01932970-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-10-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01932970-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01932970-etelcalcetide-v1
- Content SHA-256: `04e10df796516ad9060fff4563cd8eadf255218746d1758b1fa59e201b54e0d4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01932970 ([`ctg-observation-nct01932970-2018-10-17-85d8837c2345`](#source-ctg-observation-nct01932970-2018-10-17-85d8837c2345))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01932970 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01932970-2018-10-17-85d8837c2345`](#source-ctg-observation-nct01932970-2018-10-17-85d8837c2345))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01932970 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct01932970-2018-10-17-85d8837c2345`](#source-ctg-observation-nct01932970-2018-10-17-85d8837c2345))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01932970-2018-10-17-85d8837c2345`](#source-ctg-observation-nct01932970-2018-10-17-85d8837c2345))

### Sources

<a id="source-ctg-observation-nct01932970-2018-10-17-85d8837c2345"></a>
- **ClinicalTrials.gov record NCT01932970 · retained source version 2018-10-17:85d8837c2345fddcf04742f37967eae81cf24b9429644f7c4f2191425cedea8c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01932970) (`ctg-observation-nct01932970-2018-10-17-85d8837c2345`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01932970." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct01932970-etelcalcetide-v1 SHA-256: 04e10df796516ad9060fff4563cd8eadf255218746d1758b1fa59e201b54e0d4.

---

<a id="clinicaltrials-gov-nct02102204-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT02102204

> PeptideScanner retained ClinicalTrials.gov record NCT02102204 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-11-17, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct02102204-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02102204-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct02102204-etelcalcetide-v1
- Content SHA-256: `04983c77988bc4ae039a353cab1d98399d320745a3318e171cc97de79fe3208f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02102204 ([`ctg-observation-nct02102204-2017-11-17-85bee952a46d`](#source-ctg-observation-nct02102204-2017-11-17-85bee952a46d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02102204 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-11-17, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct02102204-2017-11-17-85bee952a46d`](#source-ctg-observation-nct02102204-2017-11-17-85bee952a46d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02102204 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-11-17, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct02102204-2017-11-17-85bee952a46d`](#source-ctg-observation-nct02102204-2017-11-17-85bee952a46d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02102204-2017-11-17-85bee952a46d`](#source-ctg-observation-nct02102204-2017-11-17-85bee952a46d))

### Sources

<a id="source-ctg-observation-nct02102204-2017-11-17-85bee952a46d"></a>
- **ClinicalTrials.gov record NCT02102204 · retained source version 2017-11-17:85bee952a46d8998ba3cc8fa8a72507e953d63ff8d2a6425006c55b654e3de50** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02102204) (`ctg-observation-nct02102204-2017-11-17-85bee952a46d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02102204." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct02102204-etelcalcetide-v1 SHA-256: 04983c77988bc4ae039a353cab1d98399d320745a3318e171cc97de79fe3208f.

---

<a id="clinicaltrials-gov-nct02833857-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT02833857

> PeptideScanner retained ClinicalTrials.gov record NCT02833857 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct02833857-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-07-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02833857-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct02833857-etelcalcetide-v1
- Content SHA-256: `c06d6f6aa6948f677f1245db313c8d47ecb786b3f5d5c71e0bb42301690c6627`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02833857 ([`ctg-observation-nct02833857-2019-07-10-594d0112c2cf`](#source-ctg-observation-nct02833857-2019-07-10-594d0112c2cf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02833857 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-10, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct02833857-2019-07-10-594d0112c2cf`](#source-ctg-observation-nct02833857-2019-07-10-594d0112c2cf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02833857 at 2026-11-15T22:07:29.454Z. Its registry update date was 2019-07-10, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct02833857-2019-07-10-594d0112c2cf`](#source-ctg-observation-nct02833857-2019-07-10-594d0112c2cf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02833857-2019-07-10-594d0112c2cf`](#source-ctg-observation-nct02833857-2019-07-10-594d0112c2cf))

### Sources

<a id="source-ctg-observation-nct02833857-2019-07-10-594d0112c2cf"></a>
- **ClinicalTrials.gov record NCT02833857 · retained source version 2019-07-10:594d0112c2cfa1cbfd2b0ddb1a46b15f1ddcd0376d12023a881a7cbfae51e036** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02833857) (`ctg-observation-nct02833857-2019-07-10-594d0112c2cf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02833857." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct02833857-etelcalcetide-v1 SHA-256: c06d6f6aa6948f677f1245db313c8d47ecb786b3f5d5c71e0bb42301690c6627.

---

<a id="clinicaltrials-gov-nct03283098-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT03283098

> PeptideScanner retained ClinicalTrials.gov record NCT03283098 at 2026-11-15T22:07:29.454Z. Its registry update date was 2020-02-10, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct03283098-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03283098-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03283098-etelcalcetide-v1
- Content SHA-256: `56b835f78bc82fb7b1a27944905596f3ee392d80103718b46faa72d6c45677d4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03283098 ([`ctg-observation-nct03283098-2020-02-10-f87a14e29762`](#source-ctg-observation-nct03283098-2020-02-10-f87a14e29762))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03283098 at 2026-11-15T22:07:29.454Z. Its registry update date was 2020-02-10, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03283098-2020-02-10-f87a14e29762`](#source-ctg-observation-nct03283098-2020-02-10-f87a14e29762))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03283098 at 2026-11-15T22:07:29.454Z. Its registry update date was 2020-02-10, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03283098-2020-02-10-f87a14e29762`](#source-ctg-observation-nct03283098-2020-02-10-f87a14e29762))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03283098-2020-02-10-f87a14e29762`](#source-ctg-observation-nct03283098-2020-02-10-f87a14e29762))

### Sources

<a id="source-ctg-observation-nct03283098-2020-02-10-f87a14e29762"></a>
- **ClinicalTrials.gov record NCT03283098 · retained source version 2020-02-10:f87a14e29762d147c51bccdd3ea03ee4055ebd015c7a68236d7b1e7e355f02eb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03283098) (`ctg-observation-nct03283098-2020-02-10-f87a14e29762`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03283098." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03283098-etelcalcetide-v1 SHA-256: 56b835f78bc82fb7b1a27944905596f3ee392d80103718b46faa72d6c45677d4.

---

<a id="clinicaltrials-gov-nct03299244-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT03299244

> PeptideScanner retained ClinicalTrials.gov record NCT03299244 at 2026-11-15T22:07:29.454Z. Its registry update date was 2021-04-30, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct03299244-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-04-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03299244-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03299244-etelcalcetide-v1
- Content SHA-256: `81c3bc8af3f42e8eaf6aaa8cc241b0e689ebf906f1bea3cbdd53bab5ca2265b5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03299244 ([`ctg-observation-nct03299244-2021-04-30-cca0785f47ad`](#source-ctg-observation-nct03299244-2021-04-30-cca0785f47ad))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03299244 at 2026-11-15T22:07:29.454Z. Its registry update date was 2021-04-30, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03299244-2021-04-30-cca0785f47ad`](#source-ctg-observation-nct03299244-2021-04-30-cca0785f47ad))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03299244 at 2026-11-15T22:07:29.454Z. Its registry update date was 2021-04-30, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03299244-2021-04-30-cca0785f47ad`](#source-ctg-observation-nct03299244-2021-04-30-cca0785f47ad))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03299244-2021-04-30-cca0785f47ad`](#source-ctg-observation-nct03299244-2021-04-30-cca0785f47ad))

### Sources

<a id="source-ctg-observation-nct03299244-2021-04-30-cca0785f47ad"></a>
- **ClinicalTrials.gov record NCT03299244 · retained source version 2021-04-30:cca0785f47adb3960d566ea9e16205f944438ab809ed10c00de82d5161cf5d68** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03299244) (`ctg-observation-nct03299244-2021-04-30-cca0785f47ad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03299244." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03299244-etelcalcetide-v1 SHA-256: 81c3bc8af3f42e8eaf6aaa8cc241b0e689ebf906f1bea3cbdd53bab5ca2265b5.

---

<a id="clinicaltrials-gov-nct03633708-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT03633708

> PeptideScanner retained ClinicalTrials.gov record NCT03633708 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct03633708-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03633708-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03633708-etelcalcetide-v1
- Content SHA-256: `0ce8983a52e04004247ec54e7e1f994a8ef40f77051a5ef50a2c23a15673ac6f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03633708 ([`ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6`](#source-ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03633708 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6`](#source-ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03633708 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6`](#source-ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6`](#source-ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6))

### Sources

<a id="source-ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6"></a>
- **ClinicalTrials.gov record NCT03633708 · retained source version 2026-02-27:38bd6b4ba7d6ef76f95277bedfbe8d94c999deec36829fb9e54a557f6ffa215e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03633708) (`ctg-observation-nct03633708-2026-02-27-38bd6b4ba7d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03633708." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03633708-etelcalcetide-v1 SHA-256: 0ce8983a52e04004247ec54e7e1f994a8ef40f77051a5ef50a2c23a15673ac6f.

---

<a id="clinicaltrials-gov-nct03795558-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT03795558

> PeptideScanner retained ClinicalTrials.gov record NCT03795558 at 2026-11-15T22:07:29.454Z. Its registry update date was 2022-03-23, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct03795558-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-03-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03795558-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03795558-etelcalcetide-v1
- Content SHA-256: `c8ae750aec358efa6fa0d1a1df3e391db87bc152ba732f7dfb7b65a8eb9d6fc7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03795558 ([`ctg-observation-nct03795558-2022-03-23-714d9fec5ddb`](#source-ctg-observation-nct03795558-2022-03-23-714d9fec5ddb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03795558 at 2026-11-15T22:07:29.454Z. Its registry update date was 2022-03-23, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03795558-2022-03-23-714d9fec5ddb`](#source-ctg-observation-nct03795558-2022-03-23-714d9fec5ddb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03795558 at 2026-11-15T22:07:29.454Z. Its registry update date was 2022-03-23, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03795558-2022-03-23-714d9fec5ddb`](#source-ctg-observation-nct03795558-2022-03-23-714d9fec5ddb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03795558-2022-03-23-714d9fec5ddb`](#source-ctg-observation-nct03795558-2022-03-23-714d9fec5ddb))

### Sources

<a id="source-ctg-observation-nct03795558-2022-03-23-714d9fec5ddb"></a>
- **ClinicalTrials.gov record NCT03795558 · retained source version 2022-03-23:714d9fec5ddb03844477ba707fb019dad9016f9d6197901bfddde9856d67f2bb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03795558) (`ctg-observation-nct03795558-2022-03-23-714d9fec5ddb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03795558." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03795558-etelcalcetide-v1 SHA-256: c8ae750aec358efa6fa0d1a1df3e391db87bc152ba732f7dfb7b65a8eb9d6fc7.

---

<a id="clinicaltrials-gov-nct03960437-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT03960437

> PeptideScanner retained ClinicalTrials.gov record NCT03960437 at 2026-11-15T22:07:29.454Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct03960437-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03960437-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03960437-etelcalcetide-v1
- Content SHA-256: `bb80f1d628dbed1960599e2aa8f8cb9b6fc044f628d2959760830da9fa45eb29`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03960437 ([`ctg-observation-nct03960437-2023-09-21-a95ebb1e5298`](#source-ctg-observation-nct03960437-2023-09-21-a95ebb1e5298))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03960437 at 2026-11-15T22:07:29.454Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03960437-2023-09-21-a95ebb1e5298`](#source-ctg-observation-nct03960437-2023-09-21-a95ebb1e5298))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03960437 at 2026-11-15T22:07:29.454Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03960437-2023-09-21-a95ebb1e5298`](#source-ctg-observation-nct03960437-2023-09-21-a95ebb1e5298))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03960437-2023-09-21-a95ebb1e5298`](#source-ctg-observation-nct03960437-2023-09-21-a95ebb1e5298))

### Sources

<a id="source-ctg-observation-nct03960437-2023-09-21-a95ebb1e5298"></a>
- **ClinicalTrials.gov record NCT03960437 · retained source version 2023-09-21:a95ebb1e52985d05aa4b30be9354456e5b01f8726a9c1c50b104f65fdcf68068** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03960437) (`ctg-observation-nct03960437-2023-09-21-a95ebb1e5298`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03960437." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03960437-etelcalcetide-v1 SHA-256: bb80f1d628dbed1960599e2aa8f8cb9b6fc044f628d2959760830da9fa45eb29.

---

<a id="clinicaltrials-gov-nct03969329-etelcalcetide-v1"></a>

## ClinicalTrials.gov record NCT03969329

> PeptideScanner retained ClinicalTrials.gov record NCT03969329 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.

- Evidence object: `story:clinicaltrials-gov-nct03969329-etelcalcetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03969329-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03969329-etelcalcetide-v1
- Content SHA-256: `a6594d8f3d4a1178728af858cc981dc1f4c0eeeb19904643c5b2309e73fc1974`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03969329 ([`ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1`](#source-ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03969329 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1`](#source-ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03969329 at 2026-11-15T22:07:29.454Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was etelcalcetide. ([`ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1`](#source-ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1`](#source-ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1))

### Sources

<a id="source-ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1"></a>
- **ClinicalTrials.gov record NCT03969329 · retained source version 2026-08-21:b697ecb9dcc1da80bf6d315fc61b3903302180345469329ae5a25b55c7bc5c10** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03969329) (`ctg-observation-nct03969329-2026-08-21-b697ecb9dcc1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03969329." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#clinicaltrials-gov-nct03969329-etelcalcetide-v1 SHA-256: a6594d8f3d4a1178728af858cc981dc1f4c0eeeb19904643c5b2309e73fc1974.

---

<a id="fda-drugs-nda208325-v1"></a>

## Drugs@FDA application NDA208325

> The official Drugs@FDA dataset lists original submission 1 for NDA 208325 with status AP dated 2017-02-07, and names etelcalcetide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208325:v1`
- Evidence domain: Regulatory
- Date in source: 2017-02-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208325/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#fda-drugs-nda208325-v1
- Content SHA-256: `3e975597818d1cda2fdddcfa6762d3e39c2e782724bc7859485c3ae2f97f107c`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208325 ([`fda-drugs-nda208325-2017-02-07-023620f05ec6`](#source-fda-drugs-nda208325-2017-02-07-023620f05ec6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208325 with status AP dated 2017-02-07, and names etelcalcetide among the application record's active ingredients. ([`fda-drugs-nda208325-2017-02-07-023620f05ec6`](#source-fda-drugs-nda208325-2017-02-07-023620f05ec6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208325 with status AP dated 2017-02-07, and names etelcalcetide among the application record's active ingredients. ([`fda-drugs-nda208325-2017-02-07-023620f05ec6`](#source-fda-drugs-nda208325-2017-02-07-023620f05ec6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208325-2017-02-07-023620f05ec6`](#source-fda-drugs-nda208325-2017-02-07-023620f05ec6))

### Sources

<a id="source-fda-drugs-nda208325-2017-02-07-023620f05ec6"></a>
- **Drugs@FDA application NDA208325 · original submission status AP · 2017-02-07 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208325%22&limit=1) (`fda-drugs-nda208325-2017-02-07-023620f05ec6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208325." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#fda-drugs-nda208325-v1 SHA-256: 3e975597818d1cda2fdddcfa6762d3e39c2e782724bc7859485c3ae2f97f107c.

---

<a id="federal-register-2018-28221-v1"></a>

## Federal Register notice 2018-28221

> The Federal Register published notice 2018-28221, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,” and PeptideScanner's exact reviewed identity mapping connects the document to Etelcalcetide.

- Evidence object: `story:federal-register-2018-28221:v1`
- Evidence domain: Regulatory
- Date in source: 2018-12-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-28221/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#federal-register-2018-28221-v1
- Content SHA-256: `10265bbdbb0c3e0e5d25593152dd3e1a81291772b4280abc4dfc84b553eacb23`

### Claims and source pins

#### Headline

Federal Register notice 2018-28221 ([`federal-register-2018-28221-e300dd1839c7`](#source-federal-register-2018-28221-e300dd1839c7))

#### Summary

The Federal Register published notice 2018-28221, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,” and PeptideScanner's exact reviewed identity mapping connects the document to Etelcalcetide. ([`federal-register-2018-28221-e300dd1839c7`](#source-federal-register-2018-28221-e300dd1839c7))

#### Paragraph 1

The Federal Register published notice 2018-28221, attributed to FDA and its parent HHS department, on 2018-12-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,” and PeptideScanner's exact reviewed identity mapping connects the document to Etelcalcetide. ([`federal-register-2018-28221-e300dd1839c7`](#source-federal-register-2018-28221-e300dd1839c7))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-28221-e300dd1839c7`](#source-federal-register-2018-28221-e300dd1839c7))

### Sources

<a id="source-federal-register-2018-28221-e300dd1839c7"></a>
- **Federal Register notice 2018-28221 · published 2018-12-28 · Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28221.pdf) (`federal-register-2018-28221-e300dd1839c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-28221." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#federal-register-2018-28221-v1 SHA-256: 10265bbdbb0c3e0e5d25593152dd3e1a81291772b4280abc4dfc84b553eacb23.

---

<a id="pubmed-pmid-27639083-etelcalcetide-v1"></a>

## Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

> PubMed lists PMID 27639083 in CPT: pharmacometrics & systems pharmacology as Journal Article, with publication-date metadata of 2016-09-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27639083-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27639083-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-27639083-etelcalcetide-v1
- Content SHA-256: `9d6da84f6280f053ae1d8d866f6e15c32d25aacb1c8df5fe43b617fb3bd68c5a`

### Claims and source pins

#### Headline

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ([`pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c`](#source-pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c))

#### Summary

PubMed lists PMID 27639083 in CPT: pharmacometrics & systems pharmacology as Journal Article, with publication-date metadata of 2016-09-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c`](#source-pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c))

#### Paragraph 1

PubMed lists PMID 27639083 in CPT: pharmacometrics & systems pharmacology as Journal Article, with publication-date metadata of 2016-09-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c`](#source-pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c`](#source-pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c))

### Sources

<a id="source-pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c"></a>
- **Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. · retained source version 1:2019-12-10:current:68bd2ce3fe0c1d044d44bba4ac22a9ed8e6c0c0c0da10999ae9c4ae52c0f9e64** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27639083/) (`pubmed-observation-pmid-27639083-2019-12-10-68bd2ce3fe0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-27639083-etelcalcetide-v1 SHA-256: 9d6da84f6280f053ae1d8d866f6e15c32d25aacb1c8df5fe43b617fb3bd68c5a.

---

<a id="pubmed-pmid-28063122-etelcalcetide-v1"></a>

## Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.

> PubMed lists PMID 28063122 in Journal of pharmacokinetics and pharmacodynamics as Journal Article, with publication-date metadata of 2017-01-06 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28063122-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28063122-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28063122-etelcalcetide-v1
- Content SHA-256: `277dd4469064d0b3db69cf6f56d71be921d5a923a7a2edfb5e4c8bec734e7867`

### Claims and source pins

#### Headline

Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ([`pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0`](#source-pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0))

#### Summary

PubMed lists PMID 28063122 in Journal of pharmacokinetics and pharmacodynamics as Journal Article, with publication-date metadata of 2017-01-06 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0`](#source-pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0))

#### Paragraph 1

PubMed lists PMID 28063122 in Journal of pharmacokinetics and pharmacodynamics as Journal Article, with publication-date metadata of 2017-01-06 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0`](#source-pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0`](#source-pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0))

### Sources

<a id="source-pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0"></a>
- **Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. · retained source version 1:2026-10-11:current:6468e78b57c004bcf950b332f5cc738720e6b42b14d379d01da825a46dba9250** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28063122/) (`pubmed-observation-pmid-28063122-2026-10-11-6468e78b57c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28063122-etelcalcetide-v1 SHA-256: 277dd4469064d0b3db69cf6f56d71be921d5a923a7a2edfb5e4c8bec734e7867.

---

<a id="pubmed-pmid-28277829-etelcalcetide-v1"></a>

## Etelcalcetide for the treatment of secondary hyperparathyroidism.

> PubMed lists PMID 28277829 in Expert opinion on pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-03-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28277829-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28277829-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28277829-etelcalcetide-v1
- Content SHA-256: `6f0fae6242c40f7024585b0c157aa4afef2c74b4fbc7767d4bf6f9bd5165500c`

### Claims and source pins

#### Headline

Etelcalcetide for the treatment of secondary hyperparathyroidism. ([`pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93`](#source-pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93))

#### Summary

PubMed lists PMID 28277829 in Expert opinion on pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-03-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93`](#source-pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93))

#### Paragraph 1

PubMed lists PMID 28277829 in Expert opinion on pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-03-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93`](#source-pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93`](#source-pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93))

### Sources

<a id="source-pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93"></a>
- **Etelcalcetide for the treatment of secondary hyperparathyroidism. · retained source version 1:2019-12-10:current:5c6e83aa1d93c34a9a820fe8905a227702325cb60d999b410b45a8e081327aa1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28277829/) (`pubmed-observation-pmid-28277829-2019-12-10-5c6e83aa1d93`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Etelcalcetide for the treatment of secondary hyperparathyroidism." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28277829-etelcalcetide-v1 SHA-256: 6f0fae6242c40f7024585b0c157aa4afef2c74b4fbc7767d4bf6f9bd5165500c.

---

<a id="pubmed-pmid-28508378-etelcalcetide-v1"></a>

## Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

> PubMed lists PMID 28508378 in Clinical pharmacokinetics as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-01 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28508378-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28508378-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28508378-etelcalcetide-v1
- Content SHA-256: `8a897acb6977c867da954f7ef6798ff99f6c4b90f62ca81ae8f7fef8b1093e91`

### Claims and source pins

#### Headline

Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ([`pubmed-observation-pmid-28508378-2019-12-10-ba605561a097`](#source-pubmed-observation-pmid-28508378-2019-12-10-ba605561a097))

#### Summary

PubMed lists PMID 28508378 in Clinical pharmacokinetics as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-01 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28508378-2019-12-10-ba605561a097`](#source-pubmed-observation-pmid-28508378-2019-12-10-ba605561a097))

#### Paragraph 1

PubMed lists PMID 28508378 in Clinical pharmacokinetics as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-01 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28508378-2019-12-10-ba605561a097`](#source-pubmed-observation-pmid-28508378-2019-12-10-ba605561a097))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28508378-2019-12-10-ba605561a097`](#source-pubmed-observation-pmid-28508378-2019-12-10-ba605561a097))

### Sources

<a id="source-pubmed-observation-pmid-28508378-2019-12-10-ba605561a097"></a>
- **Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. · retained source version 1:2019-12-10:current:ba605561a0978eaa8959d5c02b776b217c53b9b170b554ee429b22d8178da4d5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28508378/) (`pubmed-observation-pmid-28508378-2019-12-10-ba605561a097`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28508378-etelcalcetide-v1 SHA-256: 8a897acb6977c867da954f7ef6798ff99f6c4b90f62ca81ae8f7fef8b1093e91.

---

<a id="pubmed-pmid-28615947-etelcalcetide-v1"></a>

## Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.

> PubMed lists PMID 28615947 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2017-06-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28615947-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28615947-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28615947-etelcalcetide-v1
- Content SHA-256: `a0ee2f6abc7fd820260030fa83d7cf47c9658ccdd7beac4f77ba6602648aee98`

### Claims and source pins

#### Headline

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. ([`pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf`](#source-pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf))

#### Summary

PubMed lists PMID 28615947 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2017-06-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf`](#source-pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf))

#### Paragraph 1

PubMed lists PMID 28615947 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2017-06-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf`](#source-pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf`](#source-pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf))

### Sources

<a id="source-pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf"></a>
- **Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. · retained source version 1:2024-03-26:current:bd82592c1ecff67f001e44658e7d0feb512158e583a104ebd5100b5e60998dcd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28615947/) (`pubmed-observation-pmid-28615947-2024-03-26-bd82592c1ecf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28615947-etelcalcetide-v1 SHA-256: a0ee2f6abc7fd820260030fa83d7cf47c9658ccdd7beac4f77ba6602648aee98.

---

<a id="pubmed-pmid-28661841-etelcalcetide-v1"></a>

## Parsabiv Could Be Pricey Addition In Care for CKD, ESRD Patients.

> PubMed lists PMID 28661841 in Managed care (Langhorne, Pa.) as Journal Article, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28661841-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-05-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28661841-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28661841-etelcalcetide-v1
- Content SHA-256: `e9ddf090149d2617c753669a3b4531e2c410228ae7200555addfca919c328ff3`

### Claims and source pins

#### Headline

Parsabiv Could Be Pricey Addition In Care for CKD, ESRD Patients. ([`pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc`](#source-pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc))

#### Summary

PubMed lists PMID 28661841 in Managed care (Langhorne, Pa.) as Journal Article, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc`](#source-pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc))

#### Paragraph 1

PubMed lists PMID 28661841 in Managed care (Langhorne, Pa.) as Journal Article, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc`](#source-pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc`](#source-pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc))

### Sources

<a id="source-pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc"></a>
- **Parsabiv Could Be Pricey Addition In Care for CKD, ESRD Patients. · retained source version 1:2019-05-23:current:6392fb4e3accd98a658594da6601a962c7a44febafcb77d8dd6535fa1f0f49e2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28661841/) (`pubmed-observation-pmid-28661841-2019-05-23-6392fb4e3acc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Parsabiv Could Be Pricey Addition In Care for CKD, ESRD Patients." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28661841-etelcalcetide-v1 SHA-256: e9ddf090149d2617c753669a3b4531e2c410228ae7200555addfca919c328ff3.

---

<a id="pubmed-pmid-28867373-etelcalcetide-v1"></a>

## Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathy…

> PubMed lists PMID 28867373 in Bone as Journal Article, with publication-date metadata of 2017-09-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28867373-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28867373-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28867373-etelcalcetide-v1
- Content SHA-256: `b23384b9cd286b029a48fb4cb6feb83ef6997ba4b64eb465cb6356c34645210d`

### Claims and source pins

#### Headline

Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathy… ([`pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4`](#source-pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4))

#### Summary

PubMed lists PMID 28867373 in Bone as Journal Article, with publication-date metadata of 2017-09-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4`](#source-pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4))

#### Paragraph 1

PubMed lists PMID 28867373 in Bone as Journal Article, with publication-date metadata of 2017-09-01 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4`](#source-pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4`](#source-pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4))

### Sources

<a id="source-pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4"></a>
- **Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. · retained source version 1:2021-12-04:current:e3d7795bc8d4ec29296b8207454996bf01626e567a364ff25b7bf392b2fe82a8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28867373/) (`pubmed-observation-pmid-28867373-2021-12-04-e3d7795bc8d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathy…." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-28867373-etelcalcetide-v1 SHA-256: b23384b9cd286b029a48fb4cb6feb83ef6997ba4b64eb465cb6356c34645210d.

---

<a id="pubmed-pmid-29276237-etelcalcetide-v1"></a>

## Formulary Drug Review: Etelcalcetide.

> PubMed lists PMID 29276237 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2017-09-25 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29276237-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29276237-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29276237-etelcalcetide-v1
- Content SHA-256: `2e280f3ed70aa93ee9e5d5bc4694f5133fc3bab8539fcb43c514f692272efc42`

### Claims and source pins

#### Headline

Formulary Drug Review: Etelcalcetide. ([`pubmed-observation-pmid-29276237-2019-11-20-007471494e9f`](#source-pubmed-observation-pmid-29276237-2019-11-20-007471494e9f))

#### Summary

PubMed lists PMID 29276237 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2017-09-25 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29276237-2019-11-20-007471494e9f`](#source-pubmed-observation-pmid-29276237-2019-11-20-007471494e9f))

#### Paragraph 1

PubMed lists PMID 29276237 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2017-09-25 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29276237-2019-11-20-007471494e9f`](#source-pubmed-observation-pmid-29276237-2019-11-20-007471494e9f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29276237-2019-11-20-007471494e9f`](#source-pubmed-observation-pmid-29276237-2019-11-20-007471494e9f))

### Sources

<a id="source-pubmed-observation-pmid-29276237-2019-11-20-007471494e9f"></a>
- **Formulary Drug Review: Etelcalcetide. · retained source version 1:2019-11-20:current:007471494e9fc5360ea70f0b481bb68335e37dc70168a36bd3189685e095f867** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29276237/) (`pubmed-observation-pmid-29276237-2019-11-20-007471494e9f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Formulary Drug Review: Etelcalcetide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29276237-etelcalcetide-v1 SHA-256: 2e280f3ed70aa93ee9e5d5bc4694f5133fc3bab8539fcb43c514f692272efc42.

---

<a id="pubmed-pmid-29440923-etelcalcetide-v1"></a>

## Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.

> PubMed lists PMID 29440923 in International journal of nephrology and renovascular disease as Journal Article, Review, with publication-date metadata of 2018-02-05 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29440923-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29440923-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29440923-etelcalcetide-v1
- Content SHA-256: `dc8c27cf8107a5df07882546d2fceb120d801680f3b1920189ed228655668bc8`

### Claims and source pins

#### Headline

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. ([`pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7`](#source-pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7))

#### Summary

PubMed lists PMID 29440923 in International journal of nephrology and renovascular disease as Journal Article, Review, with publication-date metadata of 2018-02-05 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7`](#source-pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7))

#### Paragraph 1

PubMed lists PMID 29440923 in International journal of nephrology and renovascular disease as Journal Article, Review, with publication-date metadata of 2018-02-05 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7`](#source-pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7`](#source-pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7))

### Sources

<a id="source-pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7"></a>
- **Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. · retained source version 1:2024-03-13:current:7f42ac2f90a750bfb72d3199588c250899e4a218fd2a1d9651f4cdf6db213a52** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29440923/) (`pubmed-observation-pmid-29440923-2024-03-13-7f42ac2f90a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Managing hyperparathyroidism in hemodialysis: role of etelcalcetide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29440923-etelcalcetide-v1 SHA-256: dc8c27cf8107a5df07882546d2fceb120d801680f3b1920189ed228655668bc8.

---

<a id="pubmed-pmid-29691773-etelcalcetide-v1"></a>

## Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.

> PubMed lists PMID 29691773 in PharmacoEconomics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-11 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29691773-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29691773-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29691773-etelcalcetide-v1
- Content SHA-256: `a0b6f5062468c793c54c1584d1eabdbd1783b44e617daae36739aab73197432c`

### Claims and source pins

#### Headline

Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. ([`pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602`](#source-pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602))

#### Summary

PubMed lists PMID 29691773 in PharmacoEconomics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-11 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602`](#source-pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602))

#### Paragraph 1

PubMed lists PMID 29691773 in PharmacoEconomics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-11 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602`](#source-pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602`](#source-pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602))

### Sources

<a id="source-pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602"></a>
- **Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. · retained source version 1:2026-10-12:current:8d8bd4409602d7bd0f843997097f60669c0d177679304f21ce38e7587e46839b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29691773/) (`pubmed-observation-pmid-29691773-2026-10-12-8d8bd4409602`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29691773-etelcalcetide-v1 SHA-256: a0b6f5062468c793c54c1584d1eabdbd1783b44e617daae36739aab73197432c.

---

<a id="pubmed-pmid-29719376-etelcalcetide-v1"></a>

## Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.

> PubMed lists PMID 29719376 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2018-04-19 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29719376-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-11-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29719376-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29719376-etelcalcetide-v1
- Content SHA-256: `b9852f0e157a9c15e73b8f6adbfc1421bdbc945fc9835768d6f56f5b4dcc3108`

### Claims and source pins

#### Headline

Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis. ([`pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49`](#source-pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49))

#### Summary

PubMed lists PMID 29719376 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2018-04-19 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49`](#source-pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49))

#### Paragraph 1

PubMed lists PMID 29719376 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2018-04-19 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49`](#source-pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49`](#source-pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49))

### Sources

<a id="source-pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49"></a>
- **Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis. · retained source version 1:2024-11-07:current:c8be215fce49bd0c60a8933a626a92fe26ffba126d4b8a791dab684614845285** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29719376/) (`pubmed-observation-pmid-29719376-2024-11-07-c8be215fce49`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29719376-etelcalcetide-v1 SHA-256: b9852f0e157a9c15e73b8f6adbfc1421bdbc945fc9835768d6f56f5b4dcc3108.

---

<a id="pubmed-pmid-29786181-etelcalcetide-v1"></a>

## \[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy\].

> PubMed lists PMID 29786181 in Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia as Practice Guideline, Journal Article, with publication-date metadata of 2018-05 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29786181-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29786181-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29786181-etelcalcetide-v1
- Content SHA-256: `763b9b777211098dde9a4e53c6644939f4c9b012eec7bc048dbc762f9857b469`

### Claims and source pins

#### Headline

\[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy\]. ([`pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3`](#source-pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3))

#### Summary

PubMed lists PMID 29786181 in Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia as Practice Guideline, Journal Article, with publication-date metadata of 2018-05 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3`](#source-pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3))

#### Paragraph 1

PubMed lists PMID 29786181 in Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia as Practice Guideline, Journal Article, with publication-date metadata of 2018-05 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3`](#source-pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3`](#source-pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3))

### Sources

<a id="source-pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3"></a>
- **\[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy\]. · retained source version 1:2019-12-10:current:d0678ed82ae39f8f70242810ef945350431ed7d99cd4a175e48afde3f1376dc1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29786181/) (`pubmed-observation-pmid-29786181-2019-12-10-d0678ed82ae3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29786181-etelcalcetide-v1 SHA-256: 763b9b777211098dde9a4e53c6644939f4c9b012eec7bc048dbc762f9857b469.

---

<a id="pubmed-pmid-29927050-etelcalcetide-v1"></a>

## Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide.

> PubMed lists PMID 29927050 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Case Reports, Letter, with publication-date metadata of 2018-06-21 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29927050-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29927050-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29927050-etelcalcetide-v1
- Content SHA-256: `56a680b87d94d5b06ee08df825a933d2a3892eaa40d806ffe56d10367c876dd3`

### Claims and source pins

#### Headline

Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide. ([`pubmed-observation-pmid-29927050-2019-12-10-8c305765838e`](#source-pubmed-observation-pmid-29927050-2019-12-10-8c305765838e))

#### Summary

PubMed lists PMID 29927050 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Case Reports, Letter, with publication-date metadata of 2018-06-21 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29927050-2019-12-10-8c305765838e`](#source-pubmed-observation-pmid-29927050-2019-12-10-8c305765838e))

#### Paragraph 1

PubMed lists PMID 29927050 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Case Reports, Letter, with publication-date metadata of 2018-06-21 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29927050-2019-12-10-8c305765838e`](#source-pubmed-observation-pmid-29927050-2019-12-10-8c305765838e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29927050-2019-12-10-8c305765838e`](#source-pubmed-observation-pmid-29927050-2019-12-10-8c305765838e))

### Sources

<a id="source-pubmed-observation-pmid-29927050-2019-12-10-8c305765838e"></a>
- **Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide. · retained source version 1:2019-12-10:current:8c305765838e4f7ef32baf09795c6fac1b342e1f11044d717b08c308288a8e7e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29927050/) (`pubmed-observation-pmid-29927050-2019-12-10-8c305765838e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-29927050-etelcalcetide-v1 SHA-256: 56a680b87d94d5b06ee08df825a933d2a3892eaa40d806ffe56d10367c876dd3.

---

<a id="pubmed-pmid-30009474-etelcalcetide-v1"></a>

## Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?

> PubMed lists PMID 30009474 in Seminars in dialysis as Editorial, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-07-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30009474-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30009474-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-30009474-etelcalcetide-v1
- Content SHA-256: `fc413ff7c839b65de95df24a56808949b6f5091e4bf2797ad6f874f0af641b0e`

### Claims and source pins

#### Headline

Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? ([`pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d`](#source-pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d))

#### Summary

PubMed lists PMID 30009474 in Seminars in dialysis as Editorial, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-07-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d`](#source-pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d))

#### Paragraph 1

PubMed lists PMID 30009474 in Seminars in dialysis as Editorial, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2018-07-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d`](#source-pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d`](#source-pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d))

### Sources

<a id="source-pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d"></a>
- **Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? · retained source version 1:2019-12-10:current:3eea5e65525d5e6ac562cab1ab4229b6ed9d32b45422093873a7089b0ac8ad51** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30009474/) (`pubmed-observation-pmid-30009474-2019-12-10-3eea5e65525d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-30009474-etelcalcetide-v1 SHA-256: fc413ff7c839b65de95df24a56808949b6f5091e4bf2797ad6f874f0af641b0e.

---

<a id="pubmed-pmid-30013296-etelcalcetide-v1"></a>

## Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis.

> PubMed lists PMID 30013296 in P & T : a peer-reviewed journal for formulary management as Journal Article, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30013296-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30013296-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-30013296-etelcalcetide-v1
- Content SHA-256: `1078236e7df1bb876353ce4e46b1f59ca05cec54e0a15867394051cc83f19c0e`

### Claims and source pins

#### Headline

Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis. ([`pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a`](#source-pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a))

#### Summary

PubMed lists PMID 30013296 in P & T : a peer-reviewed journal for formulary management as Journal Article, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a`](#source-pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a))

#### Paragraph 1

PubMed lists PMID 30013296 in P & T : a peer-reviewed journal for formulary management as Journal Article, with publication-date metadata of 2018-07 (month precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a`](#source-pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a`](#source-pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a))

### Sources

<a id="source-pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a"></a>
- **Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis. · retained source version 1:2024-11-09:current:5d48c19b757a1d03d966d4da360933113c00dae94a85d8ff7fc6b9d737935925** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30013296/) (`pubmed-observation-pmid-30013296-2024-11-09-5d48c19b757a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-30013296-etelcalcetide-v1 SHA-256: 1078236e7df1bb876353ce4e46b1f59ca05cec54e0a15867394051cc83f19c0e.

---

<a id="pubmed-pmid-31853791-etelcalcetide-v1"></a>

## New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology.

> PubMed lists PMID 31853791 in Journal of nephrology as Journal Article, Practice Guideline, with publication-date metadata of 2019-12-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31853791-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31853791-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-31853791-etelcalcetide-v1
- Content SHA-256: `551e2087da2fb0218bf12812271b8196afe2a000e8b385484dfb3e25ca916ea5`

### Claims and source pins

#### Headline

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. ([`pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb`](#source-pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb))

#### Summary

PubMed lists PMID 31853791 in Journal of nephrology as Journal Article, Practice Guideline, with publication-date metadata of 2019-12-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb`](#source-pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb))

#### Paragraph 1

PubMed lists PMID 31853791 in Journal of nephrology as Journal Article, Practice Guideline, with publication-date metadata of 2019-12-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb`](#source-pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb`](#source-pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb))

### Sources

<a id="source-pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb"></a>
- **New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. · retained source version 1:2021-06-04:current:3b22b6b34abb19e477faf26c847c0a1835480b56862f23a59d1e801ab61f775c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31853791/) (`pubmed-observation-pmid-31853791-2021-06-04-3b22b6b34abb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-31853791-etelcalcetide-v1 SHA-256: 551e2087da2fb0218bf12812271b8196afe2a000e8b385484dfb3e25ca916ea5.

---

<a id="pubmed-pmid-33305109-etelcalcetide-v1"></a>

## A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial).

> PubMed lists PMID 33305109 in Kidney international reports as Journal Article, with publication-date metadata of 2020-09-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33305109-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-11-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33305109-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-33305109-etelcalcetide-v1
- Content SHA-256: `e8266266918f64fbe21b8f5df2f90dbb203ffb5fe721f680d6fbc9dc5abb1ff6`

### Claims and source pins

#### Headline

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). ([`pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa`](#source-pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa))

#### Summary

PubMed lists PMID 33305109 in Kidney international reports as Journal Article, with publication-date metadata of 2020-09-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa`](#source-pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa))

#### Paragraph 1

PubMed lists PMID 33305109 in Kidney international reports as Journal Article, with publication-date metadata of 2020-09-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa`](#source-pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa`](#source-pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa))

### Sources

<a id="source-pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa"></a>
- **A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). · retained source version 1:2023-11-10:current:5b253f19f4aae3028c3b8a283393ce5ff99972110ba45167a84ba04a4369b4fc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33305109/) (`pubmed-observation-pmid-33305109-2023-11-10-5b253f19f4aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-33305109-etelcalcetide-v1 SHA-256: e8266266918f64fbe21b8f5df2f90dbb203ffb5fe721f680d6fbc9dc5abb1ff6.

---

<a id="pubmed-pmid-33825489-etelcalcetide-v1"></a>

## Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis.

> PubMed lists PMID 33825489 in Circulation research as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-07 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33825489-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-01-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33825489-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-33825489-etelcalcetide-v1
- Content SHA-256: `9fafd066bf587ec6c82b814325fe8a502211ed4c14070260ee55b83e6e455f9c`

### Claims and source pins

#### Headline

Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. ([`pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e`](#source-pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e))

#### Summary

PubMed lists PMID 33825489 in Circulation research as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-07 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e`](#source-pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e))

#### Paragraph 1

PubMed lists PMID 33825489 in Circulation research as Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-04-07 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e`](#source-pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e`](#source-pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e))

### Sources

<a id="source-pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e"></a>
- **Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. · retained source version 1:2022-01-06:current:c591d3e8507e9a57061c0ca8690907eb4bc6cecb2d01f3ddf06fdd6a41a0b1eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33825489/) (`pubmed-observation-pmid-33825489-2022-01-06-c591d3e8507e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-33825489-etelcalcetide-v1 SHA-256: 9fafd066bf587ec6c82b814325fe8a502211ed4c14070260ee55b83e6e455f9c.

---

<a id="pubmed-pmid-34787825-etelcalcetide-v1"></a>

## A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.

> PubMed lists PMID 34787825 in CEN case reports as Case Reports, Journal Article, with publication-date metadata of 2021-11-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34787825-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34787825-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-34787825-etelcalcetide-v1
- Content SHA-256: `79fe80fee0ac7ca3d8b3cf3321cc9c72fc862dcf58ebd988b7618d70540b3af4`

### Claims and source pins

#### Headline

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride. ([`pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc`](#source-pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc))

#### Summary

PubMed lists PMID 34787825 in CEN case reports as Case Reports, Journal Article, with publication-date metadata of 2021-11-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc`](#source-pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc))

#### Paragraph 1

PubMed lists PMID 34787825 in CEN case reports as Case Reports, Journal Article, with publication-date metadata of 2021-11-17 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc`](#source-pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc`](#source-pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc))

### Sources

<a id="source-pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc"></a>
- **A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride. · retained source version 1:2022-07-16:current:d824de79b3dcbdfdd726c598015ed019de7ece6d83663dac47cd75d55cb116ba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34787825/) (`pubmed-observation-pmid-34787825-2022-07-16-d824de79b3dc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-34787825-etelcalcetide-v1 SHA-256: 79fe80fee0ac7ca3d8b3cf3321cc9c72fc862dcf58ebd988b7618d70540b3af4.

---

<a id="pubmed-pmid-36611532-etelcalcetide-v1"></a>

## Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation.

> PubMed lists PMID 36611532 in Healthcare (Basel, Switzerland) as Journal Article, with publication-date metadata of 2022-12-26 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36611532-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-03-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36611532-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-36611532-etelcalcetide-v1
- Content SHA-256: `90044286c72a01ebf5036bd688fb727995fb8f42e258056c37566fe87c3d15a9`

### Claims and source pins

#### Headline

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation. ([`pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88`](#source-pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88))

#### Summary

PubMed lists PMID 36611532 in Healthcare (Basel, Switzerland) as Journal Article, with publication-date metadata of 2022-12-26 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88`](#source-pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88))

#### Paragraph 1

PubMed lists PMID 36611532 in Healthcare (Basel, Switzerland) as Journal Article, with publication-date metadata of 2022-12-26 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88`](#source-pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88`](#source-pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88))

### Sources

<a id="source-pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88"></a>
- **Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation. · retained source version 1:2023-03-08:current:2e252319ad88731d01a4bb08d2e99e7825e8305efc9e03076967d1d2606e11f1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36611532/) (`pubmed-observation-pmid-36611532-2023-03-08-2e252319ad88`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-36611532-etelcalcetide-v1 SHA-256: 90044286c72a01ebf5036bd688fb727995fb8f42e258056c37566fe87c3d15a9.

---

<a id="pubmed-pmid-36790677-etelcalcetide-v1"></a>

## Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.

> PubMed lists PMID 36790677 in International urology and nephrology as Observational Study, Journal Article, with publication-date metadata of 2023-02-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36790677-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36790677-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-36790677-etelcalcetide-v1
- Content SHA-256: `c531a6dfe27ed3839e2843f1225381317bc974bbe7f527367e4b5587fbb42e9c`

### Claims and source pins

#### Headline

Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study. ([`pubmed-observation-pmid-36790677-2026-10-31-68727c48629e`](#source-pubmed-observation-pmid-36790677-2026-10-31-68727c48629e))

#### Summary

PubMed lists PMID 36790677 in International urology and nephrology as Observational Study, Journal Article, with publication-date metadata of 2023-02-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36790677-2026-10-31-68727c48629e`](#source-pubmed-observation-pmid-36790677-2026-10-31-68727c48629e))

#### Paragraph 1

PubMed lists PMID 36790677 in International urology and nephrology as Observational Study, Journal Article, with publication-date metadata of 2023-02-15 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36790677-2026-10-31-68727c48629e`](#source-pubmed-observation-pmid-36790677-2026-10-31-68727c48629e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36790677-2026-10-31-68727c48629e`](#source-pubmed-observation-pmid-36790677-2026-10-31-68727c48629e))

### Sources

<a id="source-pubmed-observation-pmid-36790677-2026-10-31-68727c48629e"></a>
- **Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study. · retained source version 1:2026-10-31:current:68727c48629ef71cfc7df42acdeaf5342491122ce3896f4df1f1411e3688a3f0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36790677/) (`pubmed-observation-pmid-36790677-2026-10-31-68727c48629e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-36790677-etelcalcetide-v1 SHA-256: c531a6dfe27ed3839e2843f1225381317bc974bbe7f527367e4b5587fbb42e9c.

---

<a id="pubmed-pmid-37383843-etelcalcetide-v1"></a>

## Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide.

> PubMed lists PMID 37383843 in Transplant international : official journal of the European Society for Organ Transplantation as Journal Article, with publication-date metadata of 2023-06-13 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37383843-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37383843-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-37383843-etelcalcetide-v1
- Content SHA-256: `70e40a64d0e852cabd341fb6cc1211a3afc4115ed4aec41463d5624c0684f54a`

### Claims and source pins

#### Headline

Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide. ([`pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215`](#source-pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215))

#### Summary

PubMed lists PMID 37383843 in Transplant international : official journal of the European Society for Organ Transplantation as Journal Article, with publication-date metadata of 2023-06-13 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215`](#source-pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215))

#### Paragraph 1

PubMed lists PMID 37383843 in Transplant international : official journal of the European Society for Organ Transplantation as Journal Article, with publication-date metadata of 2023-06-13 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215`](#source-pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215`](#source-pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215))

### Sources

<a id="source-pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215"></a>
- **Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide. · retained source version 1:2024-03-07:current:3fcfcac80215f54ee16753ad4e3e89b86e8b89b0adf6032dd907f838da25fae3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37383843/) (`pubmed-observation-pmid-37383843-2024-03-07-3fcfcac80215`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-37383843-etelcalcetide-v1 SHA-256: 70e40a64d0e852cabd341fb6cc1211a3afc4115ed4aec41463d5624c0684f54a.

---

<a id="pubmed-pmid-38050530-etelcalcetide-v1"></a>

## Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.

> PubMed lists PMID 38050530 in Cureus as Journal Article, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38050530-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-12-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38050530-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-38050530-etelcalcetide-v1
- Content SHA-256: `e41cb01011f42163833e0d57c4d7e6fb637b740630ebcae48db0155c46b4539a`

### Claims and source pins

#### Headline

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore. ([`pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d`](#source-pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d))

#### Summary

PubMed lists PMID 38050530 in Cureus as Journal Article, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d`](#source-pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d))

#### Paragraph 1

PubMed lists PMID 38050530 in Cureus as Journal Article, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d`](#source-pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d`](#source-pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d))

### Sources

<a id="source-pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d"></a>
- **Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore. · retained source version 1:2023-12-06:current:040745c29c2d776e690ca4886ad7bff3ea7d497fc735b1b5039c9ee1d28a65c6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38050530/) (`pubmed-observation-pmid-38050530-2023-12-06-040745c29c2d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-38050530-etelcalcetide-v1 SHA-256: e41cb01011f42163833e0d57c4d7e6fb637b740630ebcae48db0155c46b4539a.

---

<a id="pubmed-pmid-39081745-etelcalcetide-v1"></a>

## Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation.

> PubMed lists PMID 39081745 in Kidney international reports as Journal Article, with publication-date metadata of 2024-04-04 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39081745-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39081745-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-39081745-etelcalcetide-v1
- Content SHA-256: `e8baa2406def14b6c752057df7f82f4d50c886877f21f2833cd6b0d03ddf4b6e`

### Claims and source pins

#### Headline

Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation. ([`pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0`](#source-pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0))

#### Summary

PubMed lists PMID 39081745 in Kidney international reports as Journal Article, with publication-date metadata of 2024-04-04 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0`](#source-pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0))

#### Paragraph 1

PubMed lists PMID 39081745 in Kidney international reports as Journal Article, with publication-date metadata of 2024-04-04 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0`](#source-pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0`](#source-pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0))

### Sources

<a id="source-pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0"></a>
- **Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation. · retained source version 1:2026-05-18:current:66f8c490dee0d01821535f2f73ffa6a044750339e177d7e0f3024457c3e4bb06** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39081745/) (`pubmed-observation-pmid-39081745-2026-05-18-66f8c490dee0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-39081745-etelcalcetide-v1 SHA-256: e8baa2406def14b6c752057df7f82f4d50c886877f21f2833cd6b0d03ddf4b6e.

---

<a id="pubmed-pmid-39557587-etelcalcetide-v1"></a>

## Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina.

> PubMed lists PMID 39557587 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Journal Article, Observational Study, Multicenter Study, with publication-date metadata of 2024-11-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39557587-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39557587-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-39557587-etelcalcetide-v1
- Content SHA-256: `4afcd2e005cdc99288ad06c7c862c2b8d9c591d5aa8d66628096917a373f0818`

### Claims and source pins

#### Headline

Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina. ([`pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8`](#source-pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8))

#### Summary

PubMed lists PMID 39557587 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Journal Article, Observational Study, Multicenter Study, with publication-date metadata of 2024-11-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8`](#source-pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8))

#### Paragraph 1

PubMed lists PMID 39557587 in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy as Journal Article, Observational Study, Multicenter Study, with publication-date metadata of 2024-11-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8`](#source-pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8`](#source-pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8))

### Sources

<a id="source-pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8"></a>
- **Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina. · retained source version 1:2026-09-10:current:0b416d0cd0c85acc14c2bd96cccc75d8e63a3ad297d6b4bde8a46d15959b0cae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39557587/) (`pubmed-observation-pmid-39557587-2026-09-10-0b416d0cd0c8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-39557587-etelcalcetide-v1 SHA-256: 4afcd2e005cdc99288ad06c7c862c2b8d9c591d5aa8d66628096917a373f0818.

---

<a id="pubmed-pmid-41307414-etelcalcetide-v1"></a>

## Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy.

> PubMed lists PMID 41307414 in Clinical nephrology as Journal Article, Observational Study, Clinical Trial, Phase IV, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41307414-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41307414-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-41307414-etelcalcetide-v1
- Content SHA-256: `7e4594d5c9c8edaf4840427d875371214f96657dcf9bb277cfdd33a1e9265d78`

### Claims and source pins

#### Headline

Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy. ([`pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8`](#source-pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8))

#### Summary

PubMed lists PMID 41307414 in Clinical nephrology as Journal Article, Observational Study, Clinical Trial, Phase IV, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8`](#source-pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8))

#### Paragraph 1

PubMed lists PMID 41307414 in Clinical nephrology as Journal Article, Observational Study, Clinical Trial, Phase IV, with publication-date metadata of 2025 (year precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8`](#source-pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8`](#source-pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8))

### Sources

<a id="source-pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8"></a>
- **Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy. · retained source version 1:2026-09-26:current:2836fa1225a8767e1d5d8e5f7cdaa32d68c4fa6de6ae594c67cc5dd1a7fa1b0a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41307414/) (`pubmed-observation-pmid-41307414-2026-09-26-2836fa1225a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-41307414-etelcalcetide-v1 SHA-256: 7e4594d5c9c8edaf4840427d875371214f96657dcf9bb277cfdd33a1e9265d78.

---

<a id="pubmed-pmid-42739661-etelcalcetide-v1"></a>

## Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up.

> PubMed lists PMID 42739661 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-08-28 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42739661-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42739661-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-42739661-etelcalcetide-v1
- Content SHA-256: `19dc56f5c6615dc52dfa64f98e4c43cd560268eb0bffa319220fe82945759d46`

### Claims and source pins

#### Headline

Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up. ([`pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2`](#source-pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2))

#### Summary

PubMed lists PMID 42739661 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-08-28 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2`](#source-pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2))

#### Paragraph 1

PubMed lists PMID 42739661 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-08-28 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2`](#source-pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2`](#source-pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2))

### Sources

<a id="source-pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2"></a>
- **Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up. · retained source version 1:2026-09-16:current:d7317de980c2831334b2b12f00799560b1c2b2e4d7eaba1a693ec4bbffd9e703** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42739661/) (`pubmed-observation-pmid-42739661-2026-09-16-d7317de980c2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-42739661-etelcalcetide-v1 SHA-256: 19dc56f5c6615dc52dfa64f98e4c43cd560268eb0bffa319220fe82945759d46.

---

<a id="pubmed-pmid-42853437-etelcalcetide-v1"></a>

## Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia.

> PubMed lists PMID 42853437 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-09 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42853437-etelcalcetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42853437-etelcalcetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-42853437-etelcalcetide-v1
- Content SHA-256: `dab83f00551b80fc9963978826668acd31c6986df313195c242fcdb4d3b5a4ed`

### Claims and source pins

#### Headline

Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia. ([`pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579`](#source-pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579))

#### Summary

PubMed lists PMID 42853437 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-09 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579`](#source-pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579))

#### Paragraph 1

PubMed lists PMID 42853437 in CEN case reports as Journal Article, Case Reports, with publication-date metadata of 2026-10-09 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579`](#source-pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579`](#source-pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579))

### Sources

<a id="source-pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579"></a>
- **Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia. · retained source version 1:2026-10-12:current:1ce7771f657969e60cab065566dadadb988be8f61fba289cb28c2a551ecc4227** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42853437/) (`pubmed-observation-pmid-42853437-2026-10-12-1ce7771f6579`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/etelcalcetide.json#pubmed-pmid-42853437-etelcalcetide-v1 SHA-256: dab83f00551b80fc9963978826668acd31c6986df313195c242fcdb4d3b5a4ed.

